Loading...
NPI 1780687277 · Sacramento, CA · Community/Retail Pharmacy
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jch Pharmacy Holdings Inc is a community/retail pharmacy provider located in Sacramento, California. This profile covers 13 Medicare and 11 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Jch Pharmacy Holdings Inc |
| Address | 3257 Folsom Blvd |
| City | Sacramento |
| State | CA |
| ZIP | 95816 |
| Taxonomy | Community/Retail Pharmacy |
| NPI Enumerated | May 27, 2005 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $68.5K |
| Medicaid | $27.1K |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
13 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 90694 | This code represents a vaccine product administered into the muscle to protect against four strains of influenza (flu). It is an inactivated, adjuvanted, preservative–free vaccine given as a 0.5 mL… | 200 | $80 | $15.1K |
| 91322 | This code represents a SARS–CoV–2 vaccine product administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 50 mcg/0.5 mL. | 70 | $140 | $10K |
| 90677 | This code represents a vaccine product administered intramuscularly to protect against pneumococcal disease, a bacterial infection. This is a 20–valent vaccine, protecting against 20 strains of the… | 30 | $280 | $9.3K |
| G0008 | Administration of influenza virus vaccine | 230 | $30 | $7.2K |
| 0124A | N/A | 170 | $40 | $7.1K |
| 91320 | This code represents a SARS–CoV–2 vaccine product (tris–sucrose formulation) administered by intramuscular injection to reduce the patient’s risk of contracting COVID–19. The dosage is 30 mcg/0.3 mL. | 50 | $130 | $6.8K |
| 0134A | N/A | 100 | $40 | $4.3K |
| 90480 | The provider administers the first or only component of a SARS–CoV–2 (COVID–19) vaccine by intramuscular injection to reduce the patient's risk of contracting COVID–19. | 100 | $40 | $3.9K |
| M0201 | Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s)… | 80 | $40 | $3K |
| 90674 | This code represents a flu vaccine product that protects against four strains of influenza. It is derived from cell cultures, contains no preservatives or antibiotics, and is administered as a 0.5 mL… | 30 | $30 | $1.1K |
Showing 1–10 of 13
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 13 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
13 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| 91322 | 1,087 | 2,250 | 70 | $140 | $17.7K |
| 91320 | 1,460 | 2,330 | 80 | $130 | $16.1K |
| 90677 | 1,314 | 4,400 | 20 | $280 | $8.8K |
| 90694 | 763 | 5,020 | 50 | $70 | $7.7K |
| 90480 | 1,866 | 3,780 | 100 | $40 | $6.4K |
| M0201 | 7 | 40 | 40 | $40 | $3.2K |
| G0008 | 1,035 | 9,800 | 50 | $30 | $3K |
| 0134A | 220 | 1,630 | 30 | $40 | $2.6K |
| 0124A | 77 | 1,930 | 30 | $40 | $2.2K |
| 90674 | 201 | 960 | 20 | $30 | $970 |
Showing 1–10 of 13
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
11 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 510 | $30 | $13.2K |
| 0002A | N/A | 150 | $30 | $5K |
| 0001A | N/A | 140 | $30 | $4.7K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 360 | $10 | $2.2K |
| 0071A | N/A | 30 | $20 | $670 |
| M0201 | Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s)… | 20 | $30 | $640 |
| 0064A | N/A | 20 | $20 | $430 |
| 0072A | N/A | 10 | $20 | $280 |
| 99401 | At an encounter separate from a preventive medicine visit, the provider offers counseling related to subjects appropriate for the patient’s age, family history, and areas of concern. The subjects… | 230 | $1 | $230 |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 70 | $0 | $0 |
Showing 1–10 of 11
How this provider's Medicaid billing volume and revenue compare to other California providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. California median
11 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 276 | 500 | 530 | $20 | $128.1K |
| 87426 | The lab analyst performs an immunoassay to qualitatively or semiquantitatively evaluate the patient blood specimen for antigens of severe acute respiratory syndrome coronavirus such as SARS–CoV–2,… | 337 | 820 | 290 | $20 | $40.7K |
| 0002A | N/A | 341 | 750 | 120 | $40 | $30.8K |
| 0001A | N/A | 371 | 790 | 130 | $40 | $29.2K |
| 0064A | N/A | 385 | 500 | 70 | $40 | $12.6K |
| 99401 | At an encounter separate from a preventive medicine visit, the provider offers counseling related to subjects appropriate for the patient’s age, family history, and areas of concern. The subjects… | 604 | 1,180 | 250 | $10 | $9K |
| 0072A | N/A | 532 | 550 | 70 | $40 | $8.7K |
| 0071A | N/A | 457 | 590 | 70 | $40 | $8.5K |
| 90471 | In this procedure, the provider administers a live attenuated vaccine using a percutaneous, intradermal, subcutaneous, or intramuscular route. | 2,774 | 3,850 | 290 | $1 | $8.2K |
| M0201 | Administration of pneumococcal, influenza, hepatitis b, and/or covid-19 vaccine inside a patient's home; reported only once per individual home per date of service when such vaccine administration(s)… | 12 | 20 | 30 | $20 | $1.6K |
Showing 1–10 of 11
Other providers in the same ZIP code as Jch Pharmacy Holdings Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Sutter Valley Hospitals | CA | General Acute Care Hospital | $0 | $105.1M |
| Elica Health Centers | CA | Federally Qualified Health Center (FQHC) | $0 | $94.3M |
| City Of Sacramento | CA | Ambulance | $3.4M | $44.8M |
| Sutter Valley Medical Foundation | CA | Clinical Medical Laboratory | $4.4M | $3.8M |
| Fort Sutter Surgery Center A California Limited Partnership | CA | Ambulatory Surgical Clinic/Center | $5.2M | $152.6K |
| Northern California P.e.t. Imaging Center | CA | Radiology Clinic/Center | $1.2M | $473.5K |
| Elma Abella | CA | Nuclear Radiology Physician | $1.7M | $0 |
| Simon Trubek | CA | Nuclear Medicine Physician | $1.5M | $0 |
| Pain Diagnostic And Treatment Center LP | CA | Ambulatory Surgical Clinic/Center | $1.5M | $0 |
| Stephen Malutich | CA | Nuclear Medicine Physician | $1.4M | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.